Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Ciccolini

Showing results (131-140 of 168) with videos related to

Pageof 17
Sort By:
BMC Cancer|May 2, 2023
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol studyGwenaelle Gravis, Patricia Marino, Daniel Olive, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 20, 2021
Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351Mélanie Donnette, Mourad Hamimed, Joseph Ciccolini, et al.
Biochimie|February 5, 2013
Optimization of trans-Resveratrol bioavailability for human therapyMarie Josephe Amiot, Beatrice Romier, Thi-Mai Anh Dao, et al.
Pharmacogenomics|May 8, 2015
Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case reportGeoffroy Venton, Julien Colle, Cedric Mercier, et al.
Cancer Chemotherapy and Pharmacology|March 1, 2023
Determination of 5-azacitidine in human plasma by LC-MS/MS: application to pharmacokinetics pilot study in MDS/AML patientsMelanie Donnette, Loic Osanno, Madeleine Giocanti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabineNicolas Magné, Jean-Louis Fischel, Alain Dubreuil, et al.
International Journal of Nanomedicine|June 29, 2018
Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancerAnne Rodallec, Jean-Michel Brunel, Sarah Giacometti, et al.
Cancer Chemotherapy and Pharmacology|November 18, 2005
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiencyJoseph Ciccolini, Cedric Mercier, Laetitia Dahan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implicationsLaetitia Dahan, Joseph Ciccolini, Alexandre Evrard, et al.
Blood Advances|March 2, 2018
CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabineRaphaelle Fanciullino, Laure Farnault, Mélanie Donnette, et al.
Pageof 17

Showing results (131-140 of 168) with videos related to

Sort By:
Pageof 17
BMC Cancer|May 2, 2023
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol studyGwenaelle Gravis, Patricia Marino, Daniel Olive, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 20, 2021
Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351Mélanie Donnette, Mourad Hamimed, Joseph Ciccolini, et al.
Biochimie|February 5, 2013
Optimization of trans-Resveratrol bioavailability for human therapyMarie Josephe Amiot, Beatrice Romier, Thi-Mai Anh Dao, et al.
Pharmacogenomics|May 8, 2015
Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case reportGeoffroy Venton, Julien Colle, Cedric Mercier, et al.
Cancer Chemotherapy and Pharmacology|March 1, 2023
Determination of 5-azacitidine in human plasma by LC-MS/MS: application to pharmacokinetics pilot study in MDS/AML patientsMelanie Donnette, Loic Osanno, Madeleine Giocanti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabineNicolas Magné, Jean-Louis Fischel, Alain Dubreuil, et al.
International Journal of Nanomedicine|June 29, 2018
Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancerAnne Rodallec, Jean-Michel Brunel, Sarah Giacometti, et al.
Cancer Chemotherapy and Pharmacology|November 18, 2005
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiencyJoseph Ciccolini, Cedric Mercier, Laetitia Dahan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implicationsLaetitia Dahan, Joseph Ciccolini, Alexandre Evrard, et al.
Blood Advances|March 2, 2018
CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabineRaphaelle Fanciullino, Laure Farnault, Mélanie Donnette, et al.
Pageof 17